• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Could Be 26% Undervalued On Phase II Progress

    Simply Wall St·10/24/2026 15:34:05
    Listen to the news

    Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) drew fresh attention after presenting updated Phase II data for sacituzumab tirumotecan plus pembrolizumab in advanced urothelial carcinoma, alongside broader pipeline and regulatory updates at the 2026 ESMO Congress.

    These ESMO data land at a time when Sichuan Kelun-Biotech Biopharmaceutical’s share price has eased in the short term but remains materially ahead over longer horizons, with a 30-day share price return down 4.68%, a 90-day share price return down 10.43%, a year-to-date share price return of 14.93%, and a very large 3-year total shareholder return that is close to 5x, reflecting long-term strength even as traders reassess near-term trial progress and regulatory headlines.

    Spot 124 healthcare AI stocks that, like Sichuan Kelun-Biotech Biopharmaceutical, are using data and targeted therapies to turn clinical catalysts into potential share price momentum.

    After a brief pullback, Sichuan Kelun-Biotech Biopharmaceutical still trades well above where it sat three years ago. Is the stronger move already behind the stock, or does the current valuation leave more runway ahead?

    Most Popular Narrative: 26% Undervalued

    The most followed narrative values Sichuan Kelun-Biotech Biopharmaceutical at HK$618.43 per share versus the last close of HK$460.4, which puts the current quote at a sizeable discount if those long range assumptions play out.

    The broad adoption of antibody drug conjugates in cancer treatment, combined with Kelun-Biotech's OptiDC platform and 9 ADC projects in the clinic, positions the company to add indications and products that can widen the revenue base over time.

    Partnerships with global pharmaceutical groups such as Merck, Ellipses and Crescent Bio, including 17 ongoing global Phase III trials, create a route for overseas launches, milestones and royalties that can supplement domestic product sales and earnings.

    See why 1 investors see Sichuan Kelun-Biotech Biopharmaceutical as 26% undervalued.

    Result: Fair Value of HK$618.43 (UNDERVALUED)

    Still, the Sichuan Kelun-Biotech Biopharmaceutical story can break in the other direction if key Phase III ADC programs disappoint, or if expected NRDL access and uptake stall.

    Find out about the key risks to this Sichuan Kelun-Biotech Biopharmaceutical narrative.

    Another View: Multiples Paint A Richer Picture For Sichuan Kelun-Biotech Biopharmaceutical

    That HK$618.43 fair value implies Sichuan Kelun-Biotech Biopharmaceutical trades at an attractive discount on future cash flows. The current P/S of 44.9x tells a very different story. It is far above the Hong Kong Biotechs industry at 8.1x, peers at 10.1x, and even the 15.2x fair ratio the market could move toward. Is the stock priced for perfection, or is it simply reflecting a rare set of growth assumptions?

    See what the numbers say about this price — find out in our valuation breakdown.

    SEHK:6990 P/S Ratio as at Oct 2026
    SEHK:6990 P/S Ratio as at Oct 2026

    Next Steps

    Mixed signals around Sichuan Kelun-Biotech Biopharmaceutical can make the story feel conflicted. Move quickly, check the numbers yourself, and see whether the balance of potential upside and downside fits your own risk tolerance by weighing the 4 key rewards and 1 important warning sign.

    Looking for more Sichuan Kelun-Biotech Biopharmaceutical style ideas?

    If Sichuan Kelun-Biotech Biopharmaceutical has you thinking bigger about your portfolio, do not stop here. The right watchlist today can shape your outcomes tomorrow.